Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)

Vaccines, Pneumococcal Conjugate Vaccine Clinical Trial

Official title:
A Prospective, Observational Study to Monitor Safety in Patients Who Were Administered With Pneumococcal Conjugate Vaccine, 7-valent (Prevenar) 0.5 mL by Intramuscular Injection

Status Completed

Clinical Trial Summary

To collect post-marketing information on the safety of Prevenar in Filipino patients

Clinical Trial Description

n/a

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

Vaccines, Pneumococcal Conjugate Vaccine

Clinical Trial Details

NCT number	NCT00683410
Study type	Observational
Source	Wyeth is now a wholly owned subsidiary of Pfizer
Contact
Status	Completed
Phase	N/A
Start date	April 2007
Completion date	October 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00574795` - Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants	Phase 3
Completed	`NCT00269672` - Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects	Phase 2
Completed	`NCT00580684` - Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children	Phase 4
Completed	`NCT00500357` - Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects	Phase 3
Completed	`NCT00581620` - Study Evaluating Prevenar Immunogenicity in High Risk Children	Phase 4
Completed	`NCT00475033` - Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants	Phase 3
Completed	`NCT00980655` - Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients	Phase 3
Completed	`NCT00676091` - Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil	Phase 3